Next Phase Pilot Study Jackson Center, PA December 2, 2024 – Halberd Corporation (OTC-PINK: "HALB”) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, ...
Early Pilot Study Data from Veteran Volunteers is Compelling. Jackson Center, PA September 4, 2024 – Halberd Corporation (OTC-PINK: "HALB”) To our shareholders. As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our ...
Introducing Tri-axTM TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal Jackson Center, PA August 26, 2024 – Halberd Corporation (OTC-PINK: "HALB”) This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing concern ...
Jackson Center, PA, July 20, 2023 -- Halberd Corporation (OTC: HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases. 2nd QUARTER 2023 ACHIEVEMENTS Mississippi State University (MSU) is well on their way in ...
Jackson Center, PA May 31, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts. Mississippi State University (MSU) has completed the impacts and sample collection for ...
Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...
Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. ...
Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...
Jackson Center, PA, January 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW AND ACHIEVEMENTS Halberd continued its R&D strategy to focus on biomedical areas where: There is ...
Q2-21 Accomplishments and Q3 Plans Jackson Center, PA, July 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) As we began the second quarter, the company, along with the rest of the country, was focused on developing antibodies against Covid-19 that could be used as therapeutic and/or diagnostic tools. Because of ...